247 related articles for article (PubMed ID: 22170794)
1. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
Haukeland JW; Dahl TB; Yndestad A; Gladhaug IP; Løberg EM; Haaland T; Konopski Z; Wium C; Aasheim ET; Johansen OE; Aukrust P; Halvorsen B; Birkeland KI
Eur J Endocrinol; 2012 Mar; 166(3):503-10. PubMed ID: 22170794
[TBL] [Abstract][Full Text] [Related]
2. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
[TBL] [Abstract][Full Text] [Related]
3. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance.
Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
Endocrinology; 2012 Jul; 153(7):2974-84. PubMed ID: 22619360
[TBL] [Abstract][Full Text] [Related]
4. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
Rametta R; Ruscica M; Dongiovanni P; Macchi C; Fracanzani AL; Steffani L; Fargion S; Magni P; Valenti L
Eur J Clin Invest; 2014 Jul; 44(7):627-33. PubMed ID: 24828988
[TBL] [Abstract][Full Text] [Related]
5. Fetuin A is a Predictor of Liver Fat in Preoperative Patients with Nonalcoholic Fatty Liver Disease.
von Loeffelholz C; Horn P; Birkenfeld AL; Claus RA; Metzing BU; Döcke S; Jahreis G; Heller R; Hoppe S; Stockmann M; Lock JF; Rieger A; Weickert MO; Settmacher U; Rauchfuß F; Pfeiffer AF; Bauer M; Sponholz C
J Invest Surg; 2016 Oct; 29(5):266-74. PubMed ID: 26980291
[TBL] [Abstract][Full Text] [Related]
6. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease.
Dogru T; Genc H; Tapan S; Aslan F; Ercin CN; Ors F; Kara M; Sertoglu E; Karslioglu Y; Bagci S; Kurt I; Sonmez A
Clin Endocrinol (Oxf); 2013 May; 78(5):712-7. PubMed ID: 22676641
[TBL] [Abstract][Full Text] [Related]
7. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A.
Jung TW; Youn BS; Choi HY; Lee SY; Hong HC; Yang SJ; Yoo HJ; Kim BH; Baik SH; Choi KM
Biochem Pharmacol; 2013 Oct; 86(7):960-9. PubMed ID: 23948064
[TBL] [Abstract][Full Text] [Related]
8. Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography.
Ballestri S; Meschiari E; Baldelli E; Musumeci FE; Romagnoli D; Trenti T; Zennaro RG; Lonardo A; Loria P
Metab Syndr Relat Disord; 2013 Aug; 11(4):289-95. PubMed ID: 23600632
[TBL] [Abstract][Full Text] [Related]
9. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease.
Celebi G; Genc H; Gurel H; Sertoglu E; Kara M; Tapan S; Acikel C; Karslioglu Y; Ercin CN; Dogru T
Saudi J Gastroenterol; 2015; 21(3):139-45. PubMed ID: 26021772
[TBL] [Abstract][Full Text] [Related]
10. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects.
Sato M; Kamada Y; Takeda Y; Kida S; Ohara Y; Fujii H; Akita M; Mizutani K; Yoshida Y; Yamada M; Hougaku H; Takehara T; Miyoshi E
Liver Int; 2015 Mar; 35(3):925-35. PubMed ID: 25627311
[TBL] [Abstract][Full Text] [Related]
11. Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease.
Malin SK; Mulya A; Fealy CE; Haus JM; Pagadala MR; Scelsi AR; Huang H; Flask CA; McCullough AJ; Kirwan JP
J Appl Physiol (1985); 2013 Oct; 115(7):988-94. PubMed ID: 23928114
[TBL] [Abstract][Full Text] [Related]
12. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
13. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss.
Reinehr T; Roth CL
J Clin Endocrinol Metab; 2008 Nov; 93(11):4479-85. PubMed ID: 18728159
[TBL] [Abstract][Full Text] [Related]
14. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
[TBL] [Abstract][Full Text] [Related]
16. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients.
Kahraman A; Sowa JP; Schlattjan M; Sydor S; Pronadl M; Wree A; Beilfuss A; Kilicarslan A; Altinbaş A; Bechmann LP; Syn WK; Gerken G; Canbay A
Clin Sci (Lond); 2013 Oct; 125(8):391-400. PubMed ID: 23627434
[TBL] [Abstract][Full Text] [Related]
17. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes.
Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
Clin Endocrinol (Oxf); 2011 Oct; 75(4):450-5. PubMed ID: 21521338
[TBL] [Abstract][Full Text] [Related]
18. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease.
Lebensztejn DM; Białokoz-Kalinowska I; Kłusek-Oksiuta M; Tarasów E; Wojtkowska M; Kaczmarski M
Adv Med Sci; 2014 Mar; 59(1):81-4. PubMed ID: 24797980
[TBL] [Abstract][Full Text] [Related]
19. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.
Sardana O; Goyal R; Bedi O
Inflammopharmacology; 2021 Aug; 29(4):1061-1074. PubMed ID: 34185201
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of the effects of chromium picolinate supplementation on serum fetuin-A, metabolic and inflammatory factors in patients with nonalcoholic fatty liver disease: A double-blind, placebo-controlled trial.
Moradi F; Kooshki F; Nokhostin F; Khoshbaten M; Bazyar H; Pourghassem Gargari B
J Trace Elem Med Biol; 2021 Jan; 63():126659. PubMed ID: 33045675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
